Skip to main content

Advertisement

SpringerLink
Log in

Translational research on human pancreatic β-cell mass expansion for the treatment of diabetes

  • Review Article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

The structural, functional, and pathological differences between human islets and rodent islets, such as mouse or rat islets, have been clarified, and research using human islets is becoming more important for elucidating the pathophysiology of diabetes and developing therapeutic strategies for diabetes. Increasing the functional human β-cell mass is a feasible method for the treatment of both type 1 and type 2 diabetes. The glucokinase-mediated glucose signaling pathway is known to promote β-cell proliferation not only in rodent models but also in humans. However, little is known about the signaling components of glucose- or glucokinase-mediated signaling pathways. Studies have gradually revealed the involvement of ER stress-related molecules, cell cycle regulators, inflammatory proteins, extracellular matrix proteins, and neurotransmitters in the glucokinase-mediated signaling pathway in β-cells. Unraveling the mechanisms of those molecules in the regulation of human β-cell mass will provide new insights into how the functional β-cell mass can be increased. The human islet distribution program is essential for human islet research. However, human islets for research are only available by import from Europe and America into Japan or Asia. Since Japanese or Asian diabetes patients possibly show different features compared with European or American diabetes patients, studies using human islets from Japanese or Asian populations have become important for the elucidation of pathophysiology in these specific population groups. This review outlines new pathways important for the regulation of human pancreatic β-cell mass and expectations regarding the establishment of a human islet distribution program in Japan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia. 2005;48(11):2221–8.

    Article  CAS  Google Scholar 

  2. Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G, et al. Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin medalist study. Diabetes. 2010;59(11):2846–53.

    Article  CAS  Google Scholar 

  3. Yu MG, Keenan HA, Shah HS, Frodsham SG, Pober D, He Z, et al. Residual beta cell function and monogenic variants in long-duration type 1 diabetes patients. J Clin Invest. 2019;129(8):3252–63.

    Article  Google Scholar 

  4. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–10.

    Article  CAS  Google Scholar 

  5. Hart NJ, Powers AC. Use of human islets to understand islet biology and diabetes: progress, challenges and suggestions. Diabetologia. 2019;62(2):212–22.

    Article  CAS  Google Scholar 

  6. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci U S A. 2006;103(7):2334–9.

    Article  CAS  Google Scholar 

  7. van der Meulen T, Donaldson CJ, Caceres E, Hunter AE, Cowing-Zitron C, Pound LD, et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat Med. 2015;21(7):769–76.

    Article  Google Scholar 

  8. Kaddis JS, Olack BJ, Sowinski J, Cravens J, Contreras JL, Niland JC. Human pancreatic islets and diabetes research. JAMA. 2009;301(15):1580–7.

    Article  CAS  Google Scholar 

  9. Kulkarni RN, Stewart AF. Summary of the Keystone islet workshop (April 2014): the increasing demand for human islet availability in diabetes research. Diabetes. 2014;63(12):3979–81.

    Article  CAS  Google Scholar 

  10. Levitt HE, Cyphert TJ, Pascoe JL, Hollern DA, Abraham N, Lundell RJ, et al. Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice. Diabetologia. 2011;54(3):572–82.

    Article  CAS  Google Scholar 

  11. Shirakawa J, Terauchi Y. Newer perspective on the coupling between glucose-mediated signaling and beta-cell functionality. Endocr J. 2020;67(1):1–8.

    Article  CAS  Google Scholar 

  12. Kassem S, Bhandari S, Rodriguez-Bada P, Motaghedi R, Heyman M, Garcia-Gimeno MA, et al. Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl J Med. 2010;362(14):1348–50.

    Article  CAS  Google Scholar 

  13. Shirakawa J, Tanami R, Togashi Y, Tajima K, Orime K, Kubota N, et al. Effects of liraglutide on beta-cell-specific glucokinase-deficient neonatal mice. Endocrinology. 2012;153(7):3066–75.

    Article  CAS  Google Scholar 

  14. Kawamori D, Shirakawa J, Liew CW, Hu J, Morioka T, Duttaroy A, et al. GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in betaIRKO mice. Diabetologia. 2017;60(8):1442–53.

    Article  CAS  Google Scholar 

  15. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011;60(4):1246–57.

    Article  CAS  Google Scholar 

  16. Shirakawa J, Amo K, Ohminami H, Orime K, Togashi Y, Ito Y, et al. Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased beta cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes. J Biol Chem. 2011;286(29):25467–76.

    Article  Google Scholar 

  17. Shirakawa J, Togashi Y, Sakamoto E, Kaji M, Tajima K, Orime K, et al. Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic beta-cells. Diabetes. 2013;62(10):3448–58.

    Article  CAS  Google Scholar 

  18. Gunton JE, Kulkarni RN, Yim S, Okada T, Hawthorne WJ, Tseng YH, et al. Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell. 2005;122(3):337–49.

    Article  CAS  Google Scholar 

  19. Shirakawa J, Fernandez M, Takatani T, El Ouaamari A, Jungtrakoon P, Okawa ER, et al. Insulin signaling regulates the FoxM1/PLK1/CENP-A pathway to promote adaptive pancreatic beta cell proliferation. Cell Metab. 2017;25(4):868–82.

    Article  CAS  Google Scholar 

  20. Shirakawa J, Okuyama T, Yoshida E, Shimizu M, Horigome Y, Tuno T, et al. Effects of the antitumor drug OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, on the glycemic control, beta-cell functions, and beta-cell proliferation in male mice. Endocrinology. 2014;155(6):2102–11.

    Article  Google Scholar 

  21. Shirakawa J, Tajima K, Okuyama T, Kyohara M, Togashi Y, De Jesus DF, et al. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. Diabetologia. 2020;63(3):577–87.

    Article  CAS  Google Scholar 

  22. Inoue H, Shirakawa J, Togashi Y, Tajima K, Okuyama T, Kyohara M, et al. Signaling between pancreatic beta cells and macrophages via S100 calcium-binding protein A8 exacerbates beta-cell apoptosis and islet inflammation. J Biol Chem. 2018;293(16):5934–46.

    Article  CAS  Google Scholar 

  23. Ji Y, Sun S, Shrestha N, Darragh LB, Shirakawa J, Xing Y, et al. Toll-like receptors TLR2 and TLR4 block the replication of pancreatic beta cells in diet-induced obesity. Nat Immunol. 2019;20(6):677–86.

    Article  CAS  Google Scholar 

  24. Okuyama T, Shirakawa J, Yanagisawa H, Kyohara M, Yamazaki S, Tajima K, et al. Identification of the matricellular protein Fibulin-5 as a target molecule of glucokinase-mediated calcineurin/NFAT signaling in pancreatic islets. Sci Rep. 2017;7(1):2364.

    Article  Google Scholar 

Download references

Acknowledgements

A summary of this review was presented in the Lilly Award Lecture at the 64th Annual Meeting of the Japan Diabetes Society, Kanazawa, Japan. I would like to express sincere gratitude to Professor Yasuo Terauchi (Yokohama City University) and Professor Rohit N. Kulkarni (Joslin Diabetes Center) for their mentoring and to my colleagues and collaborators for their support. The author was supported by JSPS KAKENHI (20K08866) and AMED SICORP (192B9002).

Author information

Authors and Affiliations

  1. Laboratory and Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation (IMCR), Gunma University, Maebashi, 371-8510, Japan

    Jun Shirakawa

Authors
  1. Jun Shirakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Shirakawa.

Ethics declarations

Conflict of interest

Jun Shirakawa declares that he has no conflicts of interest associated with this research.

Human or animal rights

This article does not include data collected from any studies involving human or animal subjects.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shirakawa, J. Translational research on human pancreatic β-cell mass expansion for the treatment of diabetes. Diabetol Int 12, 349–355 (2021). https://doi.org/10.1007/s13340-021-00531-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-021-00531-4

Keywords

Search

Navigation